Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445663 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03445663: Clinical Trial Phase 1 study, sponsored by Xencor.
NCT03445663 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03445663, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
Primary Outcome
Measure of Safety
Interventions
- DRUG AMG 424
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2020-06-19 |
| Phase | Phase 1 |
Why NCT03445663 stopped before completion
NCT03445663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which AMG 424 is the first listed.
NCT03445663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03445663 about?
NCT03445663 is a clinical study titled "Study Evaluating AMG 424 in Subjects With Multiple Myeloma". A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
What is the current status of trial NCT03445663?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-07-31. Estimated completion is 2020-06-19.
What interventions are being tested in trial NCT03445663?
The interventions under investigation include: AMG 424 (DRUG).
Who is sponsoring clinical trial NCT03445663?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03445663's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI